-

Zhangmen Education Inc. Shareholder Alert: Robbins LLP Reminds Investors that Zhangmen Education Inc. (ZME) is Being Sued for Misleading Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased Zhangmen Education Inc. (NYSE: ZME) American Depository Shares ("ADSs") pursuant to the Company's June 2021 initial public offering ("IPO"). Zhangmen is an education company focused on providing personalized online courses to K-12 students in China.

If you suffered a loss due to Zhangmen Education Inc.'s misconduct, click here.

Zhangmen Education Inc. (ZME) Made False and Misleading Statements in its Offering Materials Supporting its IPO

According to the complaint, Zhangmen filed its Prospectus, which forms part of the Registration Statement for the IPO, with the Securities & Exchange Commission, offering 3.623 million ADSs at $11.50 per ADS. However, defendants failed to disclose that prior to the IPO, China had adopted stringent new regulations aimed at curbing fraud in China's online education market. This sweeping crackdown on the Chinese tutoring industry would effectively ban profit-making in the sector, essentially destroying Zhangmen's business and prospects.

On July 23, 2021, China unveiled its overhaul of the education sector, banning companies that teach school curriculum from making profits, raising capital, or going public. Zhangmen's ADSs trade at less than $1.50 per ADS.

If you purchased Zhangmen Education Inc. (ZME) ADSs pursuant to the Company's June 2021 IPO, you have until January 18, 2022, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Zhangmen Education Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

REGENXBIO, Inc. Stockholders Should Contact Robbins LLP for Information About Leading the RGNX Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026. REGENXBIO is a clinical-stage biotechnology company providing gene therapies that deliver functional genes to cells with genetic defects in the United States. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800)...

Investor Notice: Robbins LLP Informs Investors of the Gemini Space Station, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gemini Space Station, Inc. (NASDAQ: GEMI) Class A common stock pursuant and/or traceable to the Company's September 12, 2025 initial public offering ("IPO"), and/or Gemini Space Station, Inc. securities between September 12, 2025 and February 17, 2026. Gemini was founded to develop and operate a cryptocurrency platform. For more information, s...

uniQure N.V. Stockholders Should Contact Robbins LLP for Information About Leading the QURE Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? September 24, 2025 – October 31, 2025 W...
Back to Newsroom